Table 1. Clinical and Pathologic... | American Society of Hematology

Table 1.

Clinical and Pathologic Characteristics of PMBLs (Cases No. 1 Through 12) and Peripheral DLBLs (Cases No. 13 Through 20)

Case No.	Age/ Sex	Clinical Stage	Bulky Mediastinal Mass	Site of Biopsy	Other Localizations at Diagnosis	Tumor Cell Morphology (Kiel)^*
1	30/M	I	+	Mediastinum	—	cb polymorphic
2^†	37/F	IV	+	Mediastinum	Pleura, lung, cervical LN	cb polymorphic with anaplastic large-cell component
3	48/M	II	+	Mediastinum	—	cb polymorphic
4^†	34/F	IV	+	Mediastinum	Lung	cb polymorphic
5^†	32/F	I	+	Mediastinum	—	cb polymorphic
6^†	26/M	I	+	Mediastinum	—	cb polymorphic
7	31/M	I	+	Mediastinum	—	cb type with clear-cell component
8^†	23/F	I	+	Mediastinum	—	cb polymorphic
9	38/M	I	+	Mediastinum	—	cb polymorphic
10^†	41/F	II	+	Axillary LN	Axillary LN	cb type with clear-cell component
11^†	27/F	IV	+	Supra-clavicular LN	Lung, pericardium, axillary, supra-clavicular, and retroperitoneal LN	cb type with clear-cell component
12	38/M	II	+	Supra-clavicular LN	Supra-clavicular LN	cb type with clear-cell component

13	68/M	II	−	Inguinal LN	Retroperitoneal LN	T-cell–rich B-cell lymphoma
14	74/F	II	−	Supra-clavicular LN	Axillary LN	cb polymorphic
15	62/M	IV	−	Supra-clavicular LN	Spleen, BM, peripheral, and retroperitoneal LN	cb polymorphic
16	45/F	IV	−	Cervical LN	Stomach, lung, peripheral, and retroperitoneal LN	immunoblastic
17	60/F	I	−	Inguinal LN	—	cb multilobated subtype
18	57/F	IV	−	Inguinal LN	Spleen, BM, peripheral LN	cb polymorphic, high-grade transformation of a B-CLL
19	59/F	I	−	Inguinal LN	—	cb polymorphic
20	46/M	I	−	Cervical LN	—	cb polymorphic

Case No.	Age/ Sex	Clinical Stage	Bulky Mediastinal Mass	Site of Biopsy	Other Localizations at Diagnosis	Tumor Cell Morphology (Kiel)^*
1	30/M	I	+	Mediastinum	—	cb polymorphic
2^†	37/F	IV	+	Mediastinum	Pleura, lung, cervical LN	cb polymorphic with anaplastic large-cell component
3	48/M	II	+	Mediastinum	—	cb polymorphic
4^†	34/F	IV	+	Mediastinum	Lung	cb polymorphic
5^†	32/F	I	+	Mediastinum	—	cb polymorphic
6^†	26/M	I	+	Mediastinum	—	cb polymorphic
7	31/M	I	+	Mediastinum	—	cb type with clear-cell component
8^†	23/F	I	+	Mediastinum	—	cb polymorphic
9	38/M	I	+	Mediastinum	—	cb polymorphic
10^†	41/F	II	+	Axillary LN	Axillary LN	cb type with clear-cell component
11^†	27/F	IV	+	Supra-clavicular LN	Lung, pericardium, axillary, supra-clavicular, and retroperitoneal LN	cb type with clear-cell component
12	38/M	II	+	Supra-clavicular LN	Supra-clavicular LN	cb type with clear-cell component

13	68/M	II	−	Inguinal LN	Retroperitoneal LN	T-cell–rich B-cell lymphoma
14	74/F	II	−	Supra-clavicular LN	Axillary LN	cb polymorphic
15	62/M	IV	−	Supra-clavicular LN	Spleen, BM, peripheral, and retroperitoneal LN	cb polymorphic
16	45/F	IV	−	Cervical LN	Stomach, lung, peripheral, and retroperitoneal LN	immunoblastic
17	60/F	I	−	Inguinal LN	—	cb multilobated subtype
18	57/F	IV	−	Inguinal LN	Spleen, BM, peripheral LN	cb polymorphic, high-grade transformation of a B-CLL
19	59/F	I	−	Inguinal LN	—	cb polymorphic
20	46/M	I	−	Cervical LN	—	cb polymorphic

Patients were staged according to the Ann Arbor system.

Abbreviations: cb, centroblastic; LN, lymph node; BM, bone marrow; CLL, chronic lymphocytic leukemia.

All cases were classified as DLBL in the REAL classification; all cases had a CD20⁺CD3⁻ B-cell phenotype.

Cases showing variable expression of CD30 after antigen microwave retrieval.